Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10451/50788 |
Resumo: | © 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| id |
RCAP_a71ebc5c249424d0dd2149108cebe38f |
|---|---|
| oai_identifier_str |
oai:repositorio.ul.pt:10451/50788 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trialAdherenceHeart failureHyperkalaemiaMineralocorticoid receptor antagonistsPatiromerPotassiumRenin-angiotensin-aldosterone system inhibitorsTrial design© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.Aims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to ≥50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi use score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive heart failure medication. Conclusion: The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use.WileyRepositório da Universidade de LisboaButler, JavedAnker, Stefan D.Siddiqi, Tariq JamalCoats, Andrew J. S.Dorigotti, FabioFilippatos, GerasimosFriede, TimGöhring, Udo‐MichaelKosiborod, Mikhail N.Lund, Lars H.Metra, MarcoMoreno Quinn, CarolPiña, Ileana L.Pinto, Fausto J.Rossignol, PatrickSzecsödy, PeterVan Der Meer, PeterWeir, MatthewPitt, Bertram2022-01-12T15:18:47Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/50788engEur J Heart Fail. 2021 Nov 201388-984210.1002/ejhf.23861879-0844info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:55:09Zoai:repositorio.ul.pt:10451/50788Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:02:10.877538Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| title |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| spellingShingle |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial Butler, Javed Adherence Heart failure Hyperkalaemia Mineralocorticoid receptor antagonists Patiromer Potassium Renin-angiotensin-aldosterone system inhibitors Trial design |
| title_short |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| title_full |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| title_fullStr |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| title_full_unstemmed |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| title_sort |
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial |
| author |
Butler, Javed |
| author_facet |
Butler, Javed Anker, Stefan D. Siddiqi, Tariq Jamal Coats, Andrew J. S. Dorigotti, Fabio Filippatos, Gerasimos Friede, Tim Göhring, Udo‐Michael Kosiborod, Mikhail N. Lund, Lars H. Metra, Marco Moreno Quinn, Carol Piña, Ileana L. Pinto, Fausto J. Rossignol, Patrick Szecsödy, Peter Van Der Meer, Peter Weir, Matthew Pitt, Bertram |
| author_role |
author |
| author2 |
Anker, Stefan D. Siddiqi, Tariq Jamal Coats, Andrew J. S. Dorigotti, Fabio Filippatos, Gerasimos Friede, Tim Göhring, Udo‐Michael Kosiborod, Mikhail N. Lund, Lars H. Metra, Marco Moreno Quinn, Carol Piña, Ileana L. Pinto, Fausto J. Rossignol, Patrick Szecsödy, Peter Van Der Meer, Peter Weir, Matthew Pitt, Bertram |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
| dc.contributor.author.fl_str_mv |
Butler, Javed Anker, Stefan D. Siddiqi, Tariq Jamal Coats, Andrew J. S. Dorigotti, Fabio Filippatos, Gerasimos Friede, Tim Göhring, Udo‐Michael Kosiborod, Mikhail N. Lund, Lars H. Metra, Marco Moreno Quinn, Carol Piña, Ileana L. Pinto, Fausto J. Rossignol, Patrick Szecsödy, Peter Van Der Meer, Peter Weir, Matthew Pitt, Bertram |
| dc.subject.por.fl_str_mv |
Adherence Heart failure Hyperkalaemia Mineralocorticoid receptor antagonists Patiromer Potassium Renin-angiotensin-aldosterone system inhibitors Trial design |
| topic |
Adherence Heart failure Hyperkalaemia Mineralocorticoid receptor antagonists Patiromer Potassium Renin-angiotensin-aldosterone system inhibitors Trial design |
| description |
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 2021-01-01T00:00:00Z 2022-01-12T15:18:47Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/50788 |
| url |
http://hdl.handle.net/10451/50788 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Eur J Heart Fail. 2021 Nov 20 1388-9842 10.1002/ejhf.2386 1879-0844 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799134571280728064 |